Rexahn Pharmaceuticals Company Profile (NYSEMKT:RNN)

About Rexahn Pharmaceuticals (NYSEMKT:RNN)

Rexahn Pharmaceuticals logoRexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:RNN
  • CUSIP: N/A
  • Web: https://rexahn.com/cms/
Capitalization:
  • Market Cap: $57.2 million
  • Outstanding Shares: 28,459,000
Average Prices:
  • 50 Day Moving Avg: $2.49
  • 200 Day Moving Avg: $2.33
  • 52 Week Range: $0.13 - $4.74
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.96
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.56 per share
  • Price / Book: 3.59
Profitability:
  • EBITDA: ($15,840,000.00)
  • Return on Equity: 44.61%
  • Return on Assets: 15.94%
Misc:
  • Average Volume: 314,617 shs.
  • Beta: 0.14
  • Short Ratio: 6.17
 

Frequently Asked Questions for Rexahn Pharmaceuticals (NYSEMKT:RNN)

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "RNN."

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) issued its earnings results on Monday, August, 8th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.01. View Rexahn Pharmaceuticals' Earnings History.

When will Rexahn Pharmaceuticals make its next earnings announcement?

Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Rexahn Pharmaceuticals.

Where is Rexahn Pharmaceuticals' stock going? Where will Rexahn Pharmaceuticals' stock price be in 2017?

5 brokerages have issued twelve-month price objectives for Rexahn Pharmaceuticals' stock. Their predictions range from $13.00 to $20.00. On average, they expect Rexahn Pharmaceuticals' share price to reach $16.63 in the next twelve months. View Analyst Ratings for Rexahn Pharmaceuticals.

Who are some of Rexahn Pharmaceuticals' key competitors?

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:

  • Peter C. Brandt, Independent Chairman of the Board
  • Peter D. Suzdak Ph.D., Chief Executive Officer, Director
  • Tae Heum Jeong, Chief Financial Officer, Secretary
  • Ely Benaim, Chief Medical Officer
  • Charles G. Beever, Independent Director
  • Mark P. Carthy, Independent Director
  • Kwang Soo Cheong Ph.D., Independent Director
  • Richard J. Rodgers, Independent Director

How do I buy Rexahn Pharmaceuticals stock?

Shares of Rexahn Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of Rexahn Pharmaceuticals stock can currently be purchased for approximately $2.01.


MarketBeat Community Rating for Rexahn Pharmaceuticals (NYSEMKT RNN)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  250
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Rexahn Pharmaceuticals (NYSEMKT:RNN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.63
Consensus Price Target History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Price Target History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Analysts' Ratings History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Show:
DateFirmActionRatingPrice TargetDetails
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$13.00View Rating Details
9/11/2017HC WainwrightSet Price TargetBuy$20.00View Rating Details
8/7/2017Ifs SecuritiesReiterated RatingOutperformView Rating Details
6/9/2017Rodman & RenshawReiterated RatingBuy$19.50View Rating Details
6/1/2017FBR & CoReiterated RatingOutperform$30.00 -> $14.00View Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$1.75View Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Earnings by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Earnings History by Quarter for Rexahn Pharmaceuticals (NYSEMKT RNN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.21)N/AView Earnings Details
8/8/2016Q216($0.02)($0.01)ViewN/AView Earnings Details
5/9/2016Q116($0.02)($0.02)ViewN/AView Earnings Details
11/3/2015Q315($0.03)($0.02)ViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.02)ViewN/AView Earnings Details
4/6/2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015($0.02)($0.02)ViewN/AView Earnings Details
11/14/2014($0.03)($0.02)ViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.02)ViewN/AView Earnings Details
3/25/2014($0.06)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Current Year EPS Consensus Estimate: $-1.28 EPS
Next Year EPS Consensus Estimate: $-0.68 EPS

Dividends

Dividend History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Institutional Ownership by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/10/2017Chang Ho AhnDirectorSell250,000$0.70$175,000.00View SEC Filing  
1/12/2015Chang Ho AhnDirectorSell314,656$0.91$286,336.96View SEC Filing  
1/12/2015Tae Heum JeongCFOSell317,272$0.91$288,717.52View SEC Filing  
6/12/2014Chang Ho AhnDirectorSell136,193$0.99$134,831.07View SEC Filing  
9/9/2013Tae Heum JeongCFOSell71,139$0.46$32,723.94View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Latest Headlines for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Source:
DateHeadline
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 14 at 12:12 PM
finance.yahoo.com logoRexahn Announces $8 Million Registered Direct Offering
finance.yahoo.com - October 14 at 7:25 AM
nasdaq.com logoRexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher - Nasdaq
www.nasdaq.com - October 13 at 8:47 AM
finance.yahoo.com logoRexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117
finance.yahoo.com - October 11 at 7:11 AM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - October 8 at 9:16 PM
streetinsider.com logoSeaport Global Securities Starts Rexahn Pharmaceuticals Inc. (RNN) at Buy - StreetInsider.com
www.streetinsider.com - October 8 at 6:17 AM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Earns Buy Rating from Analysts at Seaport Global Securities
www.americanbankingnews.com - October 7 at 2:58 PM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 6 at 9:02 AM
finance.yahoo.com logoRexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC
finance.yahoo.com - September 22 at 4:56 PM
finance.yahoo.com logoRexahn Pharmaceuticals, Inc. (RNN) Phase 2a Update in Muscle Invasive Bladder Cancer Shows Promise, Cheers H.C. Wainwright
finance.yahoo.com - September 13 at 8:28 AM
streetinsider.com logoRexahn Pharma (RNN) Presents Final Data from Supinoxin Phase I Clinical Study and New Preclinical Data on RX ... - StreetInsider.com
www.streetinsider.com - September 12 at 9:22 AM
finance.yahoo.com logoRexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress
finance.yahoo.com - September 12 at 9:22 AM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Given a $20.00 Price Target at HC Wainwright
www.americanbankingnews.com - September 11 at 8:58 PM
feeds.benzinga.com logoRexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology (ESMO) Congress
feeds.benzinga.com - September 10 at 9:01 AM
globenewswire.com logoRexahn Pharmaceuticals to Present at 19th Annual Rodman & Renshaw Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 7 at 8:26 AM
globenewswire.com logoRexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 7:43 AM
finance.yahoo.com logoRexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical Oncology (ESMO) Congress
finance.yahoo.com - September 6 at 7:43 AM
streetinsider.com logoForm 8-K REXAHN PHARMACEUTICALS, For: Aug 29
www.streetinsider.com - September 2 at 8:10 AM
finance.yahoo.com logoRexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors
finance.yahoo.com - September 2 at 8:10 AM
streetinsider.com logoRexahn Pharma (RNN) Announces New U.S. Patent for Supinoxin
www.streetinsider.com - August 31 at 9:29 AM
finance.yahoo.com logoRexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™
finance.yahoo.com - August 31 at 9:29 AM
seekingalpha.com logoRexahn Pharma up 27% on new US nanoparticle patent - Seeking Alpha
seekingalpha.com - August 30 at 8:37 AM
finance.yahoo.com logoRexahn, Pipeline Updates, Q2 Financial Review, Analysts Target Price
finance.yahoo.com - August 30 at 8:37 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Rexahn Pharmaceuticals and Valeant Pharmaceuticals
finance.yahoo.com - August 30 at 8:37 AM
finance.yahoo.com logoRexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans
finance.yahoo.com - August 15 at 6:46 AM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) PT Set at $20.00 by HC Wainwright
www.americanbankingnews.com - August 14 at 1:06 PM
americanbankingnews.com logoIfs Securities Reaffirms "Outperform" Rating for Rexahn Pharmaceuticals, Inc. (RNN)
www.americanbankingnews.com - August 10 at 12:46 PM
finance.yahoo.com logoRexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results
finance.yahoo.com - August 8 at 6:44 AM
finance.yahoo.com logoRexahn posts 2Q profit
finance.yahoo.com - August 8 at 6:44 AM
prnewswire.com logoToday's Research Report Coverage on Biotech Stocks -- Rexahn Pharma, Protalix BioTherapeutics, Navidea ... - PR Newswire (press release)
www.prnewswire.com - July 19 at 7:20 AM
streetinsider.com logoRexahn Pharma (RNN) Granted Allowance for New US Patent Covering the Use of RX-3117 - StreetInsider.com
www.streetinsider.com - July 11 at 4:32 PM
finance.yahoo.com logoRexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117
finance.yahoo.com - July 11 at 7:11 AM
prnewswire.com logoBreakfast Technical Briefing on Biotech Stocks -- Rexahn Pharma, Novavax, and Protalix BioTherapeutics - PR Newswire (press release)
www.prnewswire.com - June 14 at 8:23 AM
streetinsider.com logoRexahn Pharma (RNN) Delivers Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in ... - StreetInsider.com
www.streetinsider.com - June 5 at 8:20 PM
globenewswire.com logoRexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in ... - GlobeNewswire (press release)
globenewswire.com - June 5 at 6:25 AM
nasdaq.com logoRexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial
www.nasdaq.com - June 4 at 9:19 AM
globenewswire.com logoStage 2 of the Study has Begun, Based on Positive Preliminary Efficacy Results from Stage 1 - GlobeNewswire (press release)
www.globenewswire.com - June 4 at 9:19 AM
globenewswire.com logoRexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 ... - GlobeNewswire (press release)
globenewswire.com - May 8 at 6:56 PM
streetinsider.com logoRexahn Pharma (RNN) to Trade on Split-Adjusted Basis at Opening; Effects 1-for-10 Reverse Stock Split
www.streetinsider.com - May 6 at 12:50 AM
streetinsider.com logoRexahn Pharma (RNN) to Trade on Split-Adjusted Basis at Opening ... - StreetInsider.com
www.streetinsider.com - May 5 at 7:53 PM
seekingalpha.com logoCould Rexahn Pharmaceuticals Have Something?
seekingalpha.com - April 17 at 6:37 PM
streetinsider.com logoRodman & Renshaw Assumes Rexahn Pharmaceuticals Inc. (RNN) at Buy - StreetInsider.com
www.streetinsider.com - April 7 at 7:56 PM
streetinsider.com logoRodman & Renshaw Assumes Rexahn Pharmaceuticals Inc. (RNN) at Buy
www.streetinsider.com - April 7 at 12:20 PM
zacks.com logoRexahn Pharmaceuticals (RNN) Jumps: Stock Moves Up 5.4%
www.zacks.com - March 16 at 8:10 AM
streetinsider.com logoRexahn Pharma (RNN): First Patient Dosed in Phase IIa, Expect Interim Efficacy Readout in 2017 - FBR - StreetInsider.com
www.streetinsider.com - March 1 at 7:51 PM
streetinsider.com logoRexahn Pharma (RNN): Niche in Pancreatic Cancer Looks ... - StreetInsider.com
www.streetinsider.com - January 24 at 8:06 AM

Social

Chart

Rexahn Pharmaceuticals (RNN) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.